On November 4, 2022, Giant Biogene Holding Co., Ltd ("Giant Biogene") (02367.HK) was successfully listed on the Main Board of the Stock Exchange of Hong Kong. Giant Biogene offered 22,608,800 shares in this global offering (before the exercise of over-allotment option) at an issue price of HK$24.30 per share, raising total proceeds of approximately HK$549 million.

Founded in 2000, Giant Biogene is a high-tech enterprise based on scientific aesthetics. The company focuses on three major industrial directions: efficacious skin care products, medical devices, functional foods and special medical use formulas, and is a pioneer and leader in China's professional skin care industry based on bioactive ingredients.

Goldman Sachs and CICC acted as the joint sponsors for the IPO.

Ernst & Young as its auditors.

Jingtian & Gongcheng and Clifford Chance as the issuer's PRC counsel and Hong Kong counsel respectively.

C&F, Freshfields Bruckhaus Deringer as PRC counsel and Hong Kong counsel for the joint sponsors, respectively.

Frost & Sullivan is its industry advisor.